Jiyue Zheng

No. 1 Xinze Road, Suzhou Industrial Park
Suzhou, 215123, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Key advances in the development of reversible covalent inhibitors.

Key advances in the development of reversible covalent inhibitors.

Journal: Future medicinal chemistry

Published: January 20, 2025

Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy.

Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy.

Journal: Journal of medicinal chemistry

Published: May 31, 2024

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines.

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines.

Journal: ChemMedChem

Published: April 24, 2020

Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.

Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.

Journal: Cell death & disease

Published: January 16, 2019

Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge.

Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge.

Journal: ACS chemical neuroscience

Published: September 11, 2018

A novel hedgehog inhibitor for the treatment of hematological malignancies.

A novel hedgehog inhibitor for the treatment of hematological malignancies.

Journal: Anti-cancer drugs

Published: August 15, 2018

GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and α-Synuclein Nitration in an MPTP Mouse Model of Parkinson's Disease.

GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and α-Synuclein Nitration in an MPTP Mouse Model of Parkinson's Disease.

Journal: Frontiers in pharmacology

Published: July 02, 2017

Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.

Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.

Journal: ACS chemical neuroscience

Published: June 16, 2017

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

Journal: ACS chemical neuroscience

Published: August 30, 2016

Metabolic Activation of Rhein: Insights into the Potential Toxicity Induced by Rhein-Containing Herbs.

Metabolic Activation of Rhein: Insights into the Potential Toxicity Induced by Rhein-Containing Herbs.

Journal: Journal of agricultural and food chemistry

Published: July 01, 2016

Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.

Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.

Journal: ACS chemical neuroscience

Published: June 13, 2014

Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.

Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.

Journal: Bioorganic & medicinal chemistry letters

Published: September 30, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026